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An exposed F-type lectin domain fused to the N-terminus of a cholesterol-dependent cytolysin scaffold
allows Streptococcus mitis lectinolysin to cluster at fucose-rich sites on target cell membranes, thereby
leading to increased pore-forming toxin activity. In this issue of Structure, Feil and coworkers define the
structural basis for lectinolysin glycan-binding specificity.Investigation of the manifold ways
whereby pathogenic bacteria engage
and disrupt host cells, tissues, and physi-
ological systems has received consider-
able scientific interest throughout the last
decade. Yet, one could easily argue that
a number of the most intriguing develop-
ments in this area have arisen not from
the identification of entirely novel classes
of toxins, but through an increasingly
detailed appreciation of unique twists
and turns onwell-establishedmechanistic
themes. It is in this regard that the so-
called cholesterol-dependent cytolysins
(CDCs) have proven particularly fasci-
nating. CDCs are a family of proteina-
ceous toxins that are expressed by five
known genera of Gram-positive bacteria
(Tweten, 2005). Whereas apparently all
CDCs are secreted in a soluble, mono-
meric form, these toxins undergo a spon-
taneous self-assembly process at their
target cell’s surface. This assembly is not
stochastic in nature, but rather consists
of discrete, step-wise transitions that are
predicated upon significant changes in
CDC secondary, tertiary, and quaternary
structures. Ultimately, this culminates in
formation of a large, membrane-spanning
b barrel-class pore of greater than 150 A˚ in
diameter and with a toxin-specific stoichi-
ometry (Tilley et al., 2005; Tweten, 2005).
Precisely how these toxins contribute to
establishment or propagation of infection
by these bacteria remains a matter for
some debate. Whereas their ability to
affect potent cellular lysis seems straight-
forward enough, it is not clear whether
host cell lysis is either beneficial or even
the primary role of CDCs in promoting
disease (Tweten, 2005).
Nearly 30 years of work laid the founda-
tion for the structure/function paradigmthat implied that cholesterol served as
the membrane receptor for CDC toxin
monomers. However, studies on Strepto-
coccus intermedius intermedilysin (ILY)
andGardnerella vaginalis vaginolysin (VLY)
demonstrated that the glycosylphosphati-
dylinositol-anchored protein CD59, rather
than cholesterol, was responsible for in-
itial binding of these CDCs to human cell
membranes (Giddings et al., 2004). As
a consequence, the general assumption
that cholesterol served as a bona fide
receptor for all CDCs required some care-
ful rethinking. It is now accepted that while
a large number of CDCs do utilize choles-
terol as their receptor (e.g., Clostridium
perfringens perfringolysin O), CDC’s strict
functional requirement for a basal per-
centage of membrane cholesterol more
generally reflects their dependence on
subtle cholesterol-dependent alterations
of local membrane properties. These
alterations, which are typically character-
istic of lipid raft structures found in host
cells, most likely promote efficient struc-
tural transitions from membrane bound
monomers, to a prepore oligomer, and
finally to the transmembrane pore proper
(Tweten, 2005).
Considerations of the precise role of
cholesterol aside, the studies on ILY and
VLY raised questions as to whether these
were the only CDCs that recognized
CD59 as their receptor. Detailed muta-
tional-based mapping of the ILY binding
site on CD59 allowed formulation of a
consensus motif that identified yet an-
other CD59-binding bacterial protein
(Wickham et al., 2011). Interestingly, this
protein from Streptococcus mitis was
originally reported as a soluble aggrega-
tion factor by virtue of its ability to alter
the light scattering properties of humanStructure 20, February 8, 2012platelets (Ohkuni et al., 1997). Subse-
quent investigation of this protein demon-
strated that it was instead a functional
CDC (Farrand et al., 2008) and that any
change in platelet behavior was most
likely due to formation of large, trans-
membrane pores rather than aggregation
as was previously believed. Curiously,
Farrand et al. (2008) also observed that
this S. mitis protein contained a lectin
domain at its N-terminus; this heretofore
undescribed feature in a CDC prompted
them to rename this protein lectinolysin
(LLY). The LLY lectin domain (denoted
LLYlec) is specific for difucosylated
glycans found in the carbohydrate anti-
gens Lewis b (Leb) and Lewis y (Ley),
and its presence in LLY is not simply
biological happenstance. Rather, LLYlec
increased the pore-forming activity of
the LLY toxin by nearly an order of magni-
tude when compared to an LLY mutant
that lacked this novel N-terminal glycan-
binding domain (denoted LLYCDC).
In this issue of Structure, Feil et al.,
(2012) report the crystal structures of
LLYlec from S. mitis in its apo form, bound
to fucose and to the difucosylated tetra-
saccharides Leb and Ley in an effort to
explain how the presence of the lectin
domain in LLY promotes its recognition
of target cell membranes. This domain
belongs to the F-type family of lectins
and is most similar to the fucose-specific
agglutinin from Anguilla anguilla (Bianchet
et al., 2002) and the carbohydrate-binding
module SpX-1 found in the virulence
factor spGH98 from Streptococcus pneu-
moniae (Boraston et al., 2006). These
lectin domains superimpose with Rms
deviations of 0.6–1.5 A˚ andadopt a jellyroll
b-barrel fold. The glycan-binding site
consists of five loops connecting theª2012 Elsevier Ltd All rights reserved 197
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arrangement reminiscent of the one found
in complementarity-determining regions
of variable immunoglobulin domains.
This satisfying structural analogy was first
elaborated for F-type lectin domains by
Bianchet and coworkers nearly 10 years
ago (Bianchet et al., 2002).
Binding of LLY to the glycans Leb and
Ley is primarily mediated by a terminal
a1,2-fucose residue, which anchors the
tetrasaccharide to the protein. The re-
maining sugar moieties form a network
of water-mediated hydrogen bonds with
the lectin to mediate specific binding to
Leb and Ley. The terminal fucose makes
exquisitely complementary interactions
with the LLY lectin domain as hydro-
phobic residues surround its aliphatic
portion, while residues His85, Arg112,
and Arg120 form hydrogen bonds with
the hydroxyl groups. The position of the
anchoring fucose moiety is only com-
patible with a terminal a1,2 linkage and
accounts for the selectivity of LLY toward
Leb and Ley along with the water-medi-
ated hydrogen bonds formed between
the protein and the remaining galactose
and fucose moieties. This sugar-binding
mode is conserved in the SpX-1/Ley
complex structure, in which the anchoring
a1,2-fucose is found in the same pocket
as in LLY, while the remaining hexose
moieties form a network of water-medi-
ated hydrogen bonds with SpX-1 resi-
dues. Not surprisingly, SpX-1 conserves
the His/Arg/Arg triad that locks fucose
into the binding pocket (Boraston et al.,
2006). Given such similar binding modes,
does LLY discriminate between Leb and
Ley glycans? Feil et al., (2012) argue that
Leb is expressed much more widely than
Ley, the expression of which is restricted
to tissues that S. mitis invades. This
suggests, at least at first glance, that Ley
is the preferred LLY ligand within the host.
Previous studies suggested that LLYlec
might remain masked within the context198 Structure 20, February 8, 2012 ª2012 Elsof a soluble monomer, yet became
exposed following LLY binding to target
cell surface since its presence enhanced
LLY activity relative to LLYcdc (Farrand
et al., 2008). In light of more recent data,
however, this model is somewhat per-
plexing since LLYcdc is now known to
contain a functional membrane-targeting
CD59-binding motif (Wickham et al.,
2011). To address this paradox from a
structural perspective, the authors carried
out a small angle X-ray scattering (SAXS)
study on full-length LLY to determine the
location of LLYlec relative to the other
four domains found within its CDC core.
Their analysis of the molecular envelope
reconstructed from the SAXS data sug-
gests that all five domains of LLY lie
largely in the same plane, with only a slight
kink between the N-terminal LLYlec region
and the remainder of the toxin. This sort of
conformation appears to accommodate
the rather small, twelve-residue peptide
sequence that links these two functionally
isolable regions quite well. Not only that,
when viewed in light of previous electron
microscopy data, it also strongly sug-
gests that the LLYlec glycan binding
domain is exposed on the outside of the
fully formed LLY pore (Tilley et al., 2005).
Given these results, it now seems that
the function of LLYlec may lie in the earliest
membrane targeting events, rather than
after the initial interaction has occurred.
What remains to be fully understood is
the nature of the fucosylated ligands
recognized by LLY under physiological
situations. Are there simply fucose-rich
regions in the vicinity of the cholesterol-
rich lipid rafts necessary for pore forma-
tion by LLY? Or could the purpose of the
LLYlec domain be to promote binding to
a specific membrane bound protein? Feil
et al., (2012) point out that CD59 presents
difucosylated ligands via its N-linked
glycans, implying that a cooperative inter-
action between these two different CD59
binding modes is theoretically possible.evier Ltd All rights reservedThese considerations aside, the authors
also raise another intriguing possibility
regarding glycan binding by LLY. Since
Ley is expressed by cells found in only
a limited number of tissue types but
is highly expressed in certain types of
cancers (Yuriev et al., 2005), could the
combined pore-forming and Ley binding
properties of the toxin be harnessed ther-
apeutically? The fact that LLY was origi-
nally isolated from the serum of patients
infected by S. mitis (Ohkuni et al., 1997)
suggests that LLY is at least somewhat
stable in human circulation. While such
a far-reaching application clearly remains
a long way off, the work presented herein
provides important foundational knowl-
edge for moving forward.REFERENCES
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